The Clinical Application of Circulating Tumor Cells and DNAs as Prognostic and Predictive Biomarkers in Gastrointestinal Cancer

Author(s): Sara Memarpour*, Ghazaleh Khalili-Tanha*, Awa Alizadeh Ghannad, Masoud Sharifian Razavi, Mona Joudi, Marjan Joodi, Gordon A. Ferns, Seyed Mahdi Hassanian, Majid Khazaei, Amir Avan*

Journal Name: Current Cancer Drug Targets

Volume 21 , Issue 8 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Gastrointestinal (GI) cancer is one of the most common cancers globally. Genetic and epigenetic mechanisms are involved in its pathogenesis. The conventional methods for diagnosis and screening for GI cancers are often invasive and have other limitations. In the era of personalized medicine, a novel non-invasive approach called liquid biopsy has been introduced for the detection and management of GI cancers, which focuses on the analysis of Circulating Tumor Cells (CTCs) and circulating cell-free tumor DNA (ctDNA). Several studies have shown that this new approach allows for an improved understanding of GI tumor biology and will lead to an improvement in clinical management. The aim of the current review is to explore the clinical applications of CTCs and ctDNA in patients with GI cancer.

Keywords: Gastrointestinal cancer, liquid biopsy, CTCs, ctDNA, biomarkers, tumor biology.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 10 March, 2021
Page: [676 - 688]
Pages: 13
DOI: 10.2174/1568009621666210311090531
Price: $65

Article Metrics

PDF: 331